These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18211497)

  • 1. Pyoderma gangrenosum--rebel without a cure?
    Jacob SE; Weisman RS; Kerdel FA
    Int J Dermatol; 2008 Feb; 47(2):192-4. PubMed ID: 18211497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
    Hubbard VG; Friedmann AC; Goldsmith P
    Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
    Reddick CL; Singh MN; Chalmers RJ
    Dermatol Online J; 2010 Aug; 16(8):15. PubMed ID: 20804692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infliximab for a girl with refractory pyoderma gangrenosum].
    Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab.
    Kleinpenning MM; Langewouters AM; Van De Kerkhof PC; Greebe RJ
    J Dermatolog Treat; 2011 Oct; 22(5):261-5. PubMed ID: 20673157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Perineal pyoderma gangrenosum in a girl treated with adalimumab after infliximab failure].
    Castro Laria L; Argüelles Arias F; García Martín M; Jiménez Contreras S; Argüelles Martín F; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Aug; 103(8):439-41. PubMed ID: 21867361
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
    Duchini G; Itin P; Arnold A
    Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recalcitrant pyoderma gangrenosum treated with thalidomide.
    Federman GL; Federman DG
    Mayo Clin Proc; 2000 Aug; 75(8):842-4. PubMed ID: 10943240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory pyoderma gangrenosum associated with ulcerative colitis successfully treated with infliximab.
    Ueda M; Katoh M; Tanizaki H; Tanioka M; Matsumura Y; Miyachi Y
    Dermatol Online J; 2012 Jan; 18(1):12. PubMed ID: 22301049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.
    Brooklyn TN; Dunnill MG; Shetty A; Bowden JJ; Williams JD; Griffiths CE; Forbes A; Greenwood R; Probert CS
    Gut; 2006 Apr; 55(4):505-9. PubMed ID: 16188920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil as therapy for pyoderma gangrenosum.
    Eaton PA; Callen JP
    Arch Dermatol; 2009 Jul; 145(7):781-5. PubMed ID: 19620559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
    Reguiaï Z; Grange F
    Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.
    Agarwal A; Andrews JM
    Aliment Pharmacol Ther; 2013 Sep; 38(6):563-72. PubMed ID: 23914999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
    Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
    Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyoderma gangrenosum.
    Conrad C; Trüeb RM
    J Dtsch Dermatol Ges; 2005 May; 3(5):334-42. PubMed ID: 16372799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
    Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
    Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pyoderma gangrenosum is 100 years old. From Louis Brocq to biotherapies].
    Farhi D; Wallach D; Avril MF
    Rev Prat; 2008 Feb; 58(4):457-61. PubMed ID: 18506988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.